U.S. Appl. No.: 10/725,284 Attorney Docket No.: 5428D1

(67824.428904)c Response dated December 19, 2007

In response to the Office Action of October 17, 2007

REMARKS

Entry of the foregoing amendments and reconsideration of the application pursuant

to and consistent with 37 CFR 1.112 and in light of the remarks which follow are

respectfully requested. By the present amendments new claims 307 and 308 are presented

which provide for the T1R2 polypeptide used in the subject assays to be expressed by a

taste or gastrointestinal cell or a tongue, palate, esophageal or stomach cell. Specific

support mat be found at least in paragraphs 27, 64-67 et seq. The other pending claims

272-306 are retained.

Claims 272-306 are rejected under double patenting grounds based on Claims 1-76

of US Patent No. 6,955,887. In addition Claims 272-306 stand rejected based on claims

287-337 of co-pending application US Serial No. 10/725,276

Applicants submit herewith Terminal Disclaimers in order to overcome the

obviousness double patenting rejections based on commonly assigned US Patent No.

6955887 and co-pending commonly assigned patent application Serial No. 10/725,276

Withdrawal of the double patenting rejections is respectfully requested.

It is anticipated that the present amendments and remarks will place this case in

condition for allowance. Based on the foregoing, a Notice to that effect is respectfully

solicited. Reconsideration and allowance of all claims are respectfully requested.

However, if any issues remain after consideration of this Amendment, Examiner Ulm is

8

U.S. Appl. No.: 10/725,284 Attorney Docket No.: 5428D1

(67824.428904)c
Response dated December 19, 2007
In response to the Office Action of October 17, 2007

respectfully requested to contact the undersigned by telephone (202-419-2018) so that these issues can be resolved by Examiner's Amendment or a Supplemental Response.

Applicants believe that no fee is due with the filing of this Amendment. However, in the event that the calculations of the Office differ, Commissioner is hereby authorized to charge or credit any such variance or credit any overpayment to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

Date: December 19, 2007

Robin L. Teskin Reg. No. 35,030

Hunton & Williams LLP 1900 K Street, N.W. Suite 1200

Washington, D.C. 20006-1109

Phone: (202) 955-1500 Fax: (202) 778-2201